致：香港交易及結算所有限公司 公司名稱: 中國天元醫療集團有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 FF301 呈交日期: 2025年9月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00557 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,720,615,042 | HKD | | 1 | HKD | | 2,720,615,042 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,720,615,042 | HKD | | 1 | HKD | | 2,720,615,042 | 第 ...

Core Viewpoint - Tianyuan Medical (00557) reported a significant decline in revenue and a reduced loss for the six months ending June 30, 2025, indicating ongoing financial challenges but some improvements in loss management [1] Financial Performance - The company achieved a revenue of HKD 8.436 million, representing a year-on-year decrease of 43.23% [1] - The loss attributable to equity holders was HKD 3.065 million, which is a reduction of 45.33% compared to the previous year [1] - The loss per share was HKD 0.77 [1] Loss Management - The reduction in loss was primarily due to a decrease in realized and unrealized valuation losses on securities by approximately HKD 600,000 [1] - The company reversed expected credit losses of about HKD 2.5 million during the period [1] - There was a significant turnaround in foreign exchange losses, with a previous loss of approximately HKD 1.9 million turning into a gain of about HKD 2.7 million [1] - Total revenue decline was offset by a reduction of approximately HKD 6.4 million [1]

[Announcement Information](index=1&type=section&id=Announcement%20Information) This section presents the disclaimer, company information, and introduction to the unaudited interim results for the period [Disclaimer](index=1&type=section&id=Disclaimer) Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited are not responsible for the content of this announcement, do not guarantee its accuracy or completeness, and expressly disclaim any liability for losses arising from reliance on its contents - Hong Kong Exchanges and the Stock Exchange are not responsible for the content of this announcement, nor do they guarantee its accuracy or completeness[1](index=1&type=chunk) - No liability is assumed for any losses arising from reliance on the content of this announcement[1](index=1&type=chunk) [Company Information and Announcement Title](index=1&type=section&id=Company%20Information%20and%20Announcement%20Title) CHINA TIAN YUAN HEALTHCARE GROUP LIMITED (Stock Code: 557) issued its unaudited consolidated interim results announcement for the six months ended June 30, 2025 - Company Name: CHINA TIAN YUAN HEALTHCARE GROUP LIMITED (中國天元醫療集團有限公司)[3](index=3&type=chunk) - Stock Code: **557**[3](index=3&type=chunk) - Announcement Type: 2025 Interim Results Announcement, covering unaudited consolidated results for the six months ended June 30, 2025[3](index=3&type=chunk) [Introduction to Results Announcement](index=1&type=section&id=Introduction%20to%20Results%20Announcement) The Company's Board of Directors announces the Group's unaudited consolidated results for the six months ended June 30, 2025, along with comparative figures - This announcement presents the unaudited consolidated results of the Company and its subsidiaries and associates (the Group) for the six months ended June 30, 2025[4](index=4&type=chunk) [Consolidated Financial Statements](index=2&type=section&id=Consolidated%20Financial%20Statements) This section presents the Group's consolidated income statement, statement of comprehensive income, and statement of financial position [Consolidated Income Statement](index=2&type=section&id=Consolidated%20Income%20Statement) For the six months ended June 30, 2025, the Group's revenue significantly decreased from HKD 14,861 thousand in 2024 to HKD 8,436 thousand, while loss for the period narrowed from HKD 8,983 thousand to HKD 5,538 thousand due to reduced cost of sales and increased reversal of expected credit losses Consolidated Income Statement Key Data (For the six months ended June 30) | Indicator | 2025 (HKD thousands) | 2024 (HKD thousands) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Revenue | 8,436 | 14,861 | -43.24% | | Cost of Sales | (303) | (5,003) | -93.95% | | Gross Profit | 8,133 | 9,858 | -17.59% | | Reversal of Expected Credit Losses | 2,496 | 399 | +525.56% | | Net Other Income / (Loss) | 2,826 | (3,050) | N/A (Turned to profit) | | Administrative Expenses | (17,350) | (14,564) | +19.13% | | Loss from Operations | (3,895) | (7,357) | -47.06% | | Loss Before Tax | (5,538) | (8,983) | -38.35% | | Loss for the Period | (5,538) | (8,983) | -38.35% | | Loss Attributable to Owners of the Company | (3,065) | (5,606) | -45.33% | | Basic Loss Per Share (HK cents) | (0.77) | (1.40) | -45.00% | [Consolidated Statement of Profit or Loss and Other Comprehensive Income](index=3&type=section&id=Consolidated%20Statement%20of%20Profit%20or%20Loss%20and%20Other%20Comprehensive%20Income) For the six months ended June 30, 2025, the Group's loss for the period narrowed, and exchange differences on translation of foreign operations increased, leading to a significant reduction in total comprehensive loss from HKD 8,390 thousand to HKD 3,451 thousand Consolidated Statement of Profit or Loss and Other Comprehensive Income Key Data (For the six months ended June 30) | Indicator | 2025 (HKD thousands) | 2024 (HKD thousands) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Loss for the Period | (5,538) | (8,983) | -38.35% | | Exchange Differences on Translation of Foreign Operations | 2,087 | 593 | +251.94% | | Total Other Comprehensive Income for the Period | 2,087 | 593 | +251.94% | | Total Comprehensive Loss for the Period | (3,451) | (8,390) | -58.86% | | Total Comprehensive Loss Attributable to Owners of the Company | (698) | (5,804) | -88.08% | [Consolidated Statement of Financial Position](index=4&type=section&id=Consolidated%20Statement%20of%20Financial%20Position) As at June 30, 2025, the Group's total assets less current liabilities slightly decreased, with a notable increase in trade and other receivables and a decrease in loans receivable, resulting in a minor decline in net assets Consolidated Statement of Financial Position Key Data (As at June 30) | Indicator | June 30, 2025 (HKD thousands) | December 31, 2024 (HKD thousands) | Change (%) | | :--- | :--- | :--- | :--- | | Non-current Assets | 85,705 | 86,147 | -0.51% | | Current Assets | 177,408 | 174,787 | +1.50% | | Current Liabilities | (54,382) | (49,252) | +10.42% | | Net Current Assets | 123,026 | 125,535 | -2.00% | | Total Assets Less Current Liabilities | 208,731 | 211,682 | -1.39% | | Non-current Liabilities | (36,231) | (35,731) | +1.40% | | Net Assets | 172,500 | 175,951 | -1.96% | | Equity Attributable to Owners of the Company | 193,984 | 194,682 | -0.36% | - Trade and other receivables (current portion) increased from **HKD 19,382 thousand** to **HKD 29,096 thousand**, an increase of approximately **50%**[7](index=7&type=chunk) - Loans receivable decreased from **HKD 127,561 thousand** to **HKD 119,353 thousand**, a decrease of approximately **6.4%**[7](index=7&type=chunk) [Notes to the Financial Statements](index=6&type=section&id=Notes%20to%20the%20Financial%20Statements) This section details the Group's accounting policies, segment reporting, various income and expense items, loss per share, dividends, and key balance sheet accounts [1. Accounting Policies](index=6&type=section&id=1.%20Accounting%20Policies) This interim results announcement is extracted from the unaudited interim financial report, prepared in accordance with HKFRS 34 and the Listing Rules, with no significant impact from new standards - The condensed consolidated interim financial statements are unaudited but have been reviewed by the audit committee[10](index=10&type=chunk) - Prepared using the same accounting policies as the annual report for the year ended December 31, 2024[10](index=10&type=chunk) - No new or revised standards not yet effective have been adopted, and their application had no significant impact on the financial position and performance for the period[10](index=10&type=chunk) [2. Revenue and Segment Reporting](index=7&type=section&id=2.%20Revenue%20and%20Segment%20Reporting) The Group's total revenue for the six months ended June 30, 2025, decreased to HKD 8,735 thousand, primarily due to a significant reduction in medical segment revenue, while the money lending segment contributed most of the revenue and profit Reportable Segment Revenue and (Loss) / Profit (For the six months ended June 30) | Segment | 2025 Revenue (HKD thousands) | 2024 Revenue (HKD thousands) | Revenue Change (%) | 2025 (Loss) / Profit (HKD thousands) | 2024 (Loss) / Profit (HKD thousands) | Profit Change (%) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Investment Holding | 299 | 265 | +12.83% | (7,644) | (9,408) | -18.75% | | Medical | 522 | 6,714 | -92.23% | (8,273) | (8,035) | +2.96% | | Money Lending and Related Business | 7,914 | 8,147 | -2.86% | 10,410 | 8,546 | +21.81% | | Hotel | – | – | N/A | (31) | (86) | -63.95% | | **Total** | **8,735** | **15,126** | **-42.25%** | **(5,538)** | **(8,983)** | **-38.35%** | - Medical segment revenue significantly decreased from **HKD 6,714 thousand** to **HKD 522 thousand**, being the primary reason for the overall revenue decline[11](index=11&type=chunk) - The money lending and related business segment was the only segment to record a profit, with a year-on-year profit growth of **21.81%**[11](index=11&type=chunk) [3. Net Other Income / (Loss)](index=8&type=section&id=3.%20Net%20Other%20Income%20%2F%20%28Loss%29) For the six months ended June 30, 2025, the Group's net other income was HKD 2,826 thousand, a significant improvement from a loss of HKD 3,050 thousand in the prior year, mainly due to a positive shift in net realized and unrealized foreign exchange gains Composition of Net Other Income / (Loss) (For the six months ended June 30) | Item | 2025 (HKD thousands) | 2024 (HKD thousands) | Change | | :--- | :--- | :--- | :--- | | Net Realized and Unrealized Foreign Exchange Gains / (Losses) | 2,723 | (1,888) | Turned from loss to gain | | Net Realized and Unrealized Valuation Losses on Trading Securities | (786) | (1,400) | Loss narrowed | | Interest Income | 299 | 265 | Increased | | Management Fee Income | 598 | – | New | | Miscellaneous Losses | (8) | (27) | Loss narrowed | | **Total** | **2,826** | **(3,050)** | **Turned from loss to gain** | [4. Administrative Expenses](index=8&type=section&id=4.%20Administrative%20Expenses) Administrative expenses primarily consist of directors' emoluments and professional fees within the investment holding segment, and staff costs in the medical segment - Administrative expenses mainly arise from the investment holding segment (directors' emoluments, professional fees) and the medical segment (staff costs)[13](index=13&type=chunk) [5. Finance Costs](index=8&type=section&id=5.%20Finance%20Costs) For the six months ended June 30, 2025, the Group's finance costs, primarily interest expenses on lease payments, slightly decreased compared to the prior year Finance Costs (For the six months ended June 30) | Item | 2025 (HKD thousands) | 2024 (HKD thousands) | Change (%) | | :--- | :--- | :--- | :--- | | Interest Expense on Lease Payments | 1,537 | 1,603 | -4.00% | [6. Income Tax Expense](index=8&type=section&id=6.%20Income%20Tax%20Expense) For the six months ended June 30, 2025, the Group incurred no income tax expense, consistent with the prior year - No provision for income tax expense was made for the current period or the prior period[15](index=15&type=chunk) [7. Loss for the Period](index=8&type=section&id=7.%20Loss%20for%20the%20Period) Loss for the period was primarily influenced by depreciation, amortization, and a significant decrease in staff costs from HKD 6,920 thousand to HKD 3,408 thousand Key Deductions for Loss for the Period (For the six months ended June 30) | Item | 2025 (HKD thousands) | 2024 (HKD thousands) | Change (%) | | :--- | :--- | :--- | :--- | | Depreciation of Property, Plant and Equipment | 248 | 354 | -29.94% | | Depreciation of Right-of-Use Assets | 2,929 | 2,690 | +8.88% | | Amortization of Intangible Assets | 1,270 | 1,132 | +12.19% | | Staff Costs (including directors' emoluments) | 3,408 | 6,920 | -50.75% | [8. Loss Per Share for the Period](index=9&type=section&id=8.%20Loss%20Per%20Share%20for%20the%20Period) The Group's basic loss per share for the six months ended June 30, 2025, narrowed to 0.77 HK cents, with diluted loss per share being identical due to the absence of dilutive securities [a) Basic Loss Per Share](index=9&type=section&id=a)%20Basic%20Loss%20Per%20Share) The basic loss per share for the period was 0.77 HK cents, reflecting a 45% reduction in loss attributable to owners of the Company Basic Loss Per Share (For the six months ended June 30) | Indicator | 2025 | 2024 | Change (%) | | :--- | :--- | :--- | :--- | | Loss Attributable to Owners of the Company (HKD thousands) | 3,065 | 5,606 | -45.33% | | Weighted Average Number of Ordinary Shares in Issue (shares) | 398,979,524 | 398,979,524 | 0.00% | | Basic Loss Per Share (HK cents) | (0.77) | (1.40) | -45.00% | [b) Diluted Loss Per Share](index=9&type=section&id=b)%20Diluted%20Loss%20Per%20Share) Diluted loss per share is identical to basic loss per share as there were no dilutive potential ordinary shares during the period - Diluted loss per share is the same as basic loss per share, as the Group had no dilutive potential ordinary shares convertible into shares during the period[17](index=17&type=chunk) [9. Dividends](index=9&type=section&id=9.%20Dividends) The Board has resolved not to declare an interim dividend for the six months ended June 30, 2025, consistent with the prior financial year [a) Interim Dividends Attributable](index=9&type=section&id=a)%20Interim%20Dividends%20Attributable) The Board has resolved not to declare an interim dividend for the six months ended June 30, 2025 - The Board has resolved not to declare an interim dividend for the six months ended June 30, 2025 (2024: nil)[18](index=18&type=chunk) [b) Dividends Attributable to the Previous Financial Year](index=9&type=section&id=b)%20Dividends%20Attributable%20to%20the%20Previous%20Financial%20Year) No dividends attributable to the previous financial year were approved or paid for the six months ended June 30, 2025 and 2024 - No dividends attributable to the previous financial year were approved and paid for the six months ended June 30, 2025 and 2024[18](index=18&type=chunk) [10. Trade and Other Receivables](index=9&type=section&id=10.%20Trade%20and%20Other%20Receivables) As at June 30, 2025, total trade and other receivables increased to HKD 32,131 thousand, driven by higher other receivables, deposits, and prepayments, while net trade receivables slightly decreased Composition of Trade and Other Receivables (As at June 30) | Item | June 30, 2025 (HKD thousands) | December 31, 2024 (HKD thousands) | Change (%) | | :--- | :--- | :--- | :--- | | Trade Receivables (net) | 3,170 | 3,939 | -19.53% | | Interest Receivables (net) | 8,633 | 7,797 | +10.72% | | Other Receivables and Deposits | 8,128 | 2,344 | +246.76% | | Prepayments | 12,200 | 8,288 | +47.19% | | **Total** | **32,131** | **22,368** | **+43.65%** | | Non-current Portion | 3,035 | 2,986 | +1.64% | | Current Portion | 29,096 | 19,382 | +50.12% | [a) Ageing Analysis](index=10&type=section&id=(a)%20Ageing%20Analysis) The ageing analysis of trade and interest receivables shows a notable increase in balances over 12 months as at June 30, 2025 Ageing Analysis of Trade and Interest Receivables (Net, as at June 30) | Ageing | June 30, 2025 (HKD thousands) | December 31, 2024 (HKD thousands) | | :--- | :--- | :--- | | Less than 1 month | 8,813 | 11,675 | | 1 to 3 months | 16 | 8 | | More than 3 months but less than 12 months | 1,666 | – | | More than 12 months | 1,308 | 53 | | **Total** | **11,803** | **11,736** | [b) Prepayments](index=10&type=section&id=(b)%20Prepayments) Prepayments, primarily for professional fees to commercial consultants, decreased from HKD 3,546 thousand to HKD 2,689 thousand - Prepayments mainly include professional fees paid in advance to commercial consultants, decreasing from **HKD 3,546 thousand** as at December 31, 2024, to **HKD 2,689 thousand**[21](index=21&type=chunk) [11. Loans Receivable](index=10&type=section&id=11.%20Loans%20Receivable) As at June 30, 2025, net loans receivable decreased to HKD 119,353 thousand, with the Group actively pursuing legal action for a significant overdue loan Composition of Loans Receivable (As at June 30) | Item | June 30, 2025 (HKD thousands) | December 31, 2024 (HKD thousands) | Change (%) | | :--- | :--- | :--- | :--- | | Loans to Third Parties | 187,668 | 197,305 | -4.93% | | Less: Provision for Expected Credit Losses | (68,315) | (69,744) | -2.05% | | **Net** | **119,353** | **127,561** | **-6.43%** | | Secured | 29,502 | 37,921 | -22.20% | | Unsecured | 89,851 | 89,640 | +0.24% | - The Group grants loans to enhance working capital efficiency and generate interest income[22](index=22&type=chunk) - For an overdue loan of approximately **HKD 102,000 thousand**, bankruptcy proceedings have been initiated against the first guarantor, with approximately **HKD 2,000** allocated, and litigation against the second guarantor is ongoing, with a judgment expected by January 24, 2026, or earlier[25](index=25&type=chunk)[26](index=26&type=chunk) - Loans bear interest at annual rates ranging from **12% to 18.5%** and are repayable within one year[26](index=26&type=chunk) [12. Trade and Other Payables](index=12&type=section&id=12.%20Trade%20and%20Other%20Payables) As at June 30, 2025, total trade and other payables increased to HKD 49,648 thousand, primarily due to an increase in amounts due to a related party, partially offset by a decrease in other payables and accrued expenses Composition of Trade and Other Payables (As at June 30) | Item | June 30, 2025 (HKD thousands) | December 31, 2024 (HKD thousands) | Change (%) | | :--- | :--- | :--- | :--- | | Trade Payables | 5,389 | 3,685 | +46.22% | | Amounts Due to a Related Party | 13,679 | – | N/A (New) | | Other Payables and Accrued Expenses | 30,580 | 40,206 | -23.94% | | **Total** | **49,648** | **43,891** | **+13.12%** | [a) Ageing Analysis](index=12&type=section&id=(a)%20Ageing%20Analysis) The ageing analysis of trade payables shows a significant increase in balances due over 12 months as at June 30, 2025 Ageing Analysis of Trade Payables (As at June 30) | Ageing | June 30, 2025 (HKD thousands) | December 31, 2024 (HKD thousands) | | :--- | :--- | :--- | | Due within 1 month or on demand | – | 189 | | Due 1 to 3 months | 18 | 18 | | Due over 3 months but less than 12 months | – | 1,761 | | Due over 12 months | 5,371 | 1,717 | | **Total** | **5,389** | **3,685** | - Trade payables due over 12 months significantly increased from **HKD 1,717 thousand** to **HKD 5,371 thousand**[28](index=28&type=chunk) [Business Review and Segment Performance](index=13&type=section&id=Business%20Review%20and%20Segment%20Performance) This section provides an overview of the Group's overall performance and detailed analysis of its medical, money lending, and investment holding segments [Overall Performance Overview](index=13&type=section&id=Overall%20Performance%20Overview) The Group's total revenue for the period was approximately HKD 8,400 thousand, a 43.6% year-on-year decrease, primarily due to a significant decline in medical business revenue, while net loss for the period narrowed to approximately HKD 5,500 thousand Overall Performance Overview (For the six months ended June 30) | Indicator | 2025 (HKD thousands) | 2024 (HKD thousands) | Change | | :--- | :--- | :--- | :--- | | Total Revenue | 8,400 | 14,900 | -43.62% | | Net Loss for the Period | (5,500) | (9,000) | -38.89% | | Net Loss Attributable to Owners of the Company | (3,100) | (5,600) | -44.64% | - The decrease in total revenue was mainly attributable to a reduction in medical business revenue from approximately **HKD 6,700 thousand** to approximately **HKD 500 thousand**[29](index=29&type=chunk) - The reduction in loss was primarily due to a decrease in net valuation losses on trading securities of approximately **HKD 600 thousand**, a reversal of expected credit losses of approximately **HKD 2,500 thousand**, and a shift from foreign exchange losses to gains of approximately **HKD 2,700 thousand**[29](index=29&type=chunk) [Medical Segment](index=13&type=section&id=Medical%20Segment) Medical segment revenue significantly dropped to approximately HKD 500 thousand due to the Shanghai hospital's temporary suspension and renovation, yet net loss narrowed to approximately HKD 4,200 thousand, with new skincare products contributing revenue - Shanghai Hospital (primarily engaged in plastic surgery) recorded zero revenue for the period and a net loss of approximately **HKD 4,200 thousand**, an improvement compared to prior year's revenue of HKD 5,900 thousand and net loss of HKD 6,300 thousand[30](index=30&type=chunk) - The decrease in Shanghai Hospital's revenue was mainly due to the temporary suspension of business operations and renovation during the period[30](index=30&type=chunk) - Pu Ai Pu recorded no royalty income for the period, a decrease of **HKD 800 thousand** compared to the prior year[31](index=31&type=chunk) - The new skincare product business recorded revenue of approximately **HKD 500 thousand** for the period[32](index=32&type=chunk) [Money Lending and Related Business Segment](index=14&type=section&id=Money%20Lending%20and%20Related%20Business%20Segment) The money lending segment recognized interest income from third-party loans of approximately HKD 7,900 thousand, and its profit before tax increased to approximately HKD 10,400 thousand due to a reversal of expected credit losses Money Lending and Related Business Segment Key Data (For the six months ended June 30) | Indicator | 2025 (HKD thousands) | 2024 (HKD thousands) | Change (%) | | :--- | :--- | :--- | :--- | | Interest Income from Third-Party Loans | 7,900 | 8,100 | -2.47% | | Reversal of Expected Credit Losses | 2,500 | N/A | N/A (New) | | Profit Before Tax | 10,400 | 8,500 | +22.35% | [Investment Holding Segment](index=14&type=section&id=Investment%20Holding%20Segment) The investment holding segment's net realized and unrealized valuation losses on trading securities narrowed to approximately HKD 800 thousand, leading to a reduced loss before tax of approximately HKD 7,600 thousand Investment Holding Segment Key Data (For the six months ended June 30) | Indicator | 2025 (HKD thousands) | 2024 (HKD thousands) | Change (%) | | :--- | :--- | :--- | :--- | | Net Realized and Unrealized Valuation Losses on Trading Securities | (800) | (1,400) | -42.86% | | Loss Before Tax | (7,600) | (9,400) | -19.15% | [Outlook](index=14&type=section&id=Outlook) This section outlines the Group's future strategies for its medical, money lending, and investment holding businesses, alongside plans for new business development [Medical Business](index=14&type=section&id=Medical%20Business) The Group plans to expand its plastic surgery and medical aesthetics services in Asia, offer management services to other hospitals, and vigorously develop its skincare product business with new product launches and multi-channel promotion - Will continue to develop and expand plastic surgery and medical aesthetics services in China and other Asian markets[35](index=35&type=chunk) - Plans to provide management and marketing services to other plastic surgery hospitals in China[35](index=35&type=chunk) - Has launched DA Mask (medical-grade mask for post-aesthetic procedures) and the skincare brand PerOyan (skincare products for full-cycle post-aesthetic care)[35](index=35&type=chunk)[36](index=36&type=chunk) - Will leverage Shanghai Hospital's customer channels to promote DA Mask and PerOyan, and promote the PerOyan brand through online platforms like Xiaohongshu and Douyin, as well as offline channels[36](index=36&type=chunk)[37](index=37&type=chunk) - The PerOyan brand received a Bazaar Beauty Annual Award in 2024[37](index=37&type=chunk) [Money Lending and Related Business](index=15&type=section&id=Money%20Lending%20and%20Related%20Business) The Group will continue its money lending and related activities, adopting more cautious credit assessment procedures due to adverse impacts like US-China trade friction, balancing expansion with risk control - Will continue money lending and related businesses, including referrals, fund matching, arrangement, and participation[38](index=38&type=chunk) - Will adopt more cautious credit assessment and procedures due to adverse impacts such as US-China trade friction[38](index=38&type=chunk) [Investment Holding](index=15&type=section&id=Investment%20Holding) The Group will continue to hold trading securities, monitor and adjust its investment portfolio, and explore short-term investment plans to improve returns on cash reserves - Will continue to hold trading securities, monitoring and adjusting the investment portfolio to adapt to the economic environment[39](index=39&type=chunk) - Will explore different short-term investment plans to improve investment returns on cash reserves[39](index=39&type=chunk) [New Business Segment](index=16&type=section&id=New%20Business%20Segment) Management is actively seeking other business opportunities to diversify and increase revenue streams beyond existing business developments - Management is actively seeking other business opportunities to achieve diversification and increase revenue streams[40](index=40&type=chunk) [Other Information and Corporate Governance](index=16&type=section&id=Other%20Information%20and%20Corporate%20Governance) This section covers the Audit Committee's review, dividend policy, corporate governance code compliance, directors' securities transactions, and listed securities activities [Audit Committee](index=16&type=section&id=Audit%20Committee) The Company's Audit Committee, comprising three independent non-executive directors, has reviewed the unaudited interim results and financial information for the period without objection - The Audit Committee comprises three independent non-executive directors[41](index=41&type=chunk) - The interim results and financial information have been reviewed, with no objections regarding their content and accounting treatment[41](index=41&type=chunk) [Dividend Policy](index=16&type=section&id=Dividend%20Policy) The Board of Directors does not recommend the payment of an interim dividend for the six months ended June 30, 2025 - The Board of Directors does not recommend the payment of an interim dividend for the six months ended June 30, 2025[42](index=42&type=chunk) [Corporate Governance Code](index=16&type=section&id=Corporate%20Governance%20Code) The Company's Chairman and CEO roles are held by the same individual, deviating from the Listing Rules, though the Board believes this does not impair power balance and is seeking a suitable candidate - The roles of Chairman and Chief Executive Officer are held by the same individual (Ms. Dong Wei), deviating from paragraph C.2.1 of the Corporate Governance Code[43](index=43&type=chunk) - The Board believes the current structure allows for effective planning and execution of corporate strategies but is committed to identifying a suitable executive director to comply with the code as soon as practicable[43](index=43&type=chunk) - Except as disclosed, the Company has complied with the Corporate Governance Code throughout the period[43](index=43&type=chunk) [Compliance with the Model Code for Securities Transactions by Directors](index=16&type=section&id=Compliance%20with%20the%20Model%20Code%20for%20Securities%20Transactions%20by%20Directors) The Company has adopted the Model Code for securities transactions by directors, and all directors have confirmed compliance throughout the period - The Company has adopted the Model Code as the code of conduct for directors' securities transactions[45](index=45&type=chunk) - All directors have confirmed compliance with the Model Code throughout the period[45](index=45&type=chunk) [Purchase, Sale or Redemption of the Company's Listed Securities](index=17&type=section&id=Purchase%2C%20Sale%20or%20Redemption%20of%20the%20Company%27s%20Listed%20Securities) Neither the Company nor its subsidiaries purchased, sold, or redeemed any of its listed securities during the period, and no treasury shares were held as at June 30, 2025 - Neither the Company nor its subsidiaries purchased, sold, or redeemed any of the Company's listed securities during the period[46](index=46&type=chunk) - As at June 30, 2025, the Company held no treasury shares[46](index=46&type=chunk)

Summary of Key Points Core Viewpoint - Tianyuan Medical (00557.HK) anticipates a significant decline in total revenue for the six months ending June 30, 2025, projecting approximately HKD 8.4 million, a decrease of about 44% compared to approximately HKD 14.9 million for the previous period [1][3]. Revenue Decline Reasons - The primary reason for the expected revenue decrease is the suspension of operations and renovations at Shanghai Yuyue Weilai Medical Beauty Hospital, which is partially owned by the group. This is expected to result in a revenue drop of no less than approximately HKD 6.2 million, reducing medical business revenue to about HKD 0.5 million (previous period: approximately HKD 6.7 million) [3]. Net Loss Projection - The company projects a net loss of approximately HKD 8.4 million for the interim period, compared to a net loss of approximately HKD 9 million for the previous period. This anticipated loss is primarily attributed to the estimated decrease in total revenue, offset by a corresponding reduction in operating costs [3]. Business Overview - Tianyuan Medical's main business activities include investment holding, providing procurement, marketing, management, franchising, and plastic surgery services to the medical industry, as well as lending and related services, and offering procurement services to the hotel industry [3].

Core Viewpoint - Tianyuan Medical (00557.HK) anticipates a total revenue of approximately HKD 8.4 million in the first half of 2025, representing a year-on-year decrease of about 44% [1] Group 1 - The expected decline in total revenue is primarily attributed to the suspension of operations and renovations at Shanghai Yuyue Weilai Medical Beauty Hospital Co., Ltd., in which the group holds partial interests [1] - The medical business revenue is projected to decrease by no less than approximately HKD 6.2 million, down to about HKD 0.5 million, compared to approximately HKD 6.7 million in the previous period [1]

Group 1 - The company, Tianyuan Medical (00557), expects total revenue of approximately HKD 8.4 million in the first half of 2025, representing a year-on-year decrease of about 44% [1] - The anticipated revenue decline is primarily due to the suspension of operations and renovations at Shanghai Yuyue Weilai Medical Beauty Hospital, which is partially owned by the group, leading to a projected revenue decrease of no less than HKD 6.2 million to approximately HKD 0.5 million (previous period: approximately HKD 6.7 million) [1] - The company expects a net loss of approximately HKD 8.4 million for the interim period, compared to a net loss of approximately HKD 9 million in the previous period, with the estimated net loss mainly attributed to the decrease in total revenue [1]

Core Viewpoint - Tianyuan Medical (00557) anticipates a significant decline in total revenue for the first half of 2025, projecting approximately HKD 8.4 million, a year-on-year decrease of about 44% [1] Revenue Forecast - The expected decrease in total revenue is primarily attributed to the suspension of operations and renovations at Shanghai Yuyue Weilai Medical Beauty Hospital, which is partially owned by the group, leading to a projected revenue drop of at least HKD 6.2 million to around HKD 0.5 million (previous period: approximately HKD 6.7 million) [1] Net Loss Projection - The group expects to incur a net loss of approximately HKD 8.4 million during the interim period (previous period: approximately HKD 9 million) [1] - The estimated net loss is mainly due to the anticipated reduction in total revenue compared to the previous period, offset by a corresponding decrease in operating costs [1]

Core Viewpoint - Tianyuan Medical (00557.HK) expects total revenue for the six months ending June 30, 2025, to be approximately HKD 8.4 million, a decrease of about 44% compared to approximately HKD 14.9 million in the previous period [1] Revenue Summary - The anticipated decrease in total revenue is primarily attributed to the suspension of operations and renovations at Shanghai Yuyue Weilai Medical Beauty Hospital, which is partially owned by the group, leading to a projected revenue drop of no less than approximately HKD 6.2 million to about HKD 500,000 (previous period: approximately HKD 6.7 million) [1] Net Loss Summary - The group expects to record a net loss of approximately HKD 8.4 million for the interim period (previous period: approximately HKD 9 million) [1] - The estimated net loss is mainly due to the anticipated decrease in total revenue, offset by a corresponding reduction in operating costs [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 中國天元醫療集團有限公司 （於開曼群島註冊成立之有限公司） （股份代號：557） 盈利警告公佈 本公佈乃由中國天元醫療集團有限公司（「本公司」，連同其附屬公司統稱「本集 團」）董事（「董事」）會（「董事會」）根據香港聯合交易所有限公司證券上市規則 （「上市規則」）第13.09(2)(a)條及香港法例第571章證券及期貨條例第XIVA部項 下的內幕消息條文（定義見上市規則）而作出。 董事會謹此知會本公司股東（「股東」）及潛在投資者，根據對本集團最近期未經 審核綜合管理賬目的初步評估及本公司目前可獲得的資料，預期本集團於截至 二零二五年六月三十日止六個月（「中期期間」）將錄得總收益約8,400,000港元， 較截至二零二四年六月三十日止六個月（「前一期間」）的約14,900,000港元減少 約44%。預期總收益減少乃主要歸因於上海愉悅薇萊醫療美容醫院有限公司（本 集團擁有部分權益及位於中華人民共和國上海市的 ...

Core Viewpoint - Tianyuan Medical (00557.HK) will hold a board meeting on August 29, 2025, to review and approve the interim results for the six months ending June 30, 2025, and to consider the proposal for an interim dividend distribution, if any [1] Summary by Categories - Company Announcement - The board meeting is scheduled for August 29, 2025 [1] - The meeting will focus on the interim results for the six months ending June 30, 2025 [1] - The board will also consider the proposal for an interim dividend distribution [1]